0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Neurodegenerative Diseases Drug Market Insights and Forecast to 2028
Published Date: May 2022
|
Report Code: QYRE-Auto-33M1920
Home | Market Reports | Business & Industrial | Pharmaceuticals & Biotech
Global Neurodegenerative Diseases Drug Market Insights and Forecast to 2028

Global Neurodegenerative Diseases Drug Market Insights and Forecast to 2028

Code: QYRE-Auto-33M1920
Report
May 2022
107 Pages
QYResearch
Region: Global, North America, Japan, Europe, Central & South America,
Description
Table of Content
Tables & Figures
Neurodegenerative disease is caused by the loss of neurons and/or their myelin sheath, which worsens over time and becomes dysfunctional. 
Market Analysis and Insights: Global Neurodegenerative Diseases Drug Market

The global Neurodegenerative Diseases Drug market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.

Fully considering the economic change by this health crisis, By Drug Class accounting for % of the Neurodegenerative Diseases Drug global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period.

While Multiple Sclerosis segment is altered to an % CAGR throughout this forecast period.
China Neurodegenerative Diseases Drug market size is valued at US$ million in 2021, while the North America and Europe Neurodegenerative Diseases Drug are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period.

As for the Europe Neurodegenerative Diseases Drug landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Neurodegenerative Diseases Drug market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Neurodegenerative Diseases Drug market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Neurodegenerative Diseases Drug market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Neurodegenerative Diseases Drug market.
Global Neurodegenerative Diseases Drug Scope and Market Size
Neurodegenerative Diseases Drug market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Neurodegenerative Diseases Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type

By Drug Class
Immunomodulator
Interferons
Decarboxylase Inhibitors
Dopamine Agonists
Others
By Route of Administration
Oral
Injection
Transdermal

Segment by Application

Multiple Sclerosis
Parkinson’s Disease
Alzheimer’s Disease
Spinal Muscular Atrophy (SMA)
Others

BY COMPANY

Biogen
Pfizer
Roche
Novartis
Sanofi
Teva Pharmaceuticals
Orion Pharma Ltd
UCB S.A
ACADIA Pharmaceuticals Inc.
Lundbeck Pharmaceuticals Italy S.p.A.
Mitsubishi Tanabe Pharma America

BY REGION

North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurodegenerative Diseases Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Immunomodulator
1.2.3 Interferons
1.2.4 Decarboxylase Inhibitors
1.2.5 Dopamine Agonists
1.2.6 Others
1.3 Market by Application
1.3.1 Global Neurodegenerative Diseases Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Multiple Sclerosis
1.3.3 Parkinson’s Disease
1.3.4 Alzheimer’s Disease
1.3.5 Spinal Muscular Atrophy (SMA)
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Neurodegenerative Diseases Drug Market Perspective (2017-2028)
2.2 Neurodegenerative Diseases Drug Growth Trends by Region
2.2.1 Neurodegenerative Diseases Drug Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Neurodegenerative Diseases Drug Historic Market Size by Region (2017-2022)
2.2.3 Neurodegenerative Diseases Drug Forecasted Market Size by Region (2023-2028)
2.3 Neurodegenerative Diseases Drug Market Dynamics
2.3.1 Neurodegenerative Diseases Drug Industry Trends
2.3.2 Neurodegenerative Diseases Drug Market Drivers
2.3.3 Neurodegenerative Diseases Drug Market Challenges
2.3.4 Neurodegenerative Diseases Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neurodegenerative Diseases Drug Players by Revenue
3.1.1 Global Top Neurodegenerative Diseases Drug Players by Revenue (2017-2022)
3.1.2 Global Neurodegenerative Diseases Drug Revenue Market Share by Players (2017-2022)
3.2 Global Neurodegenerative Diseases Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neurodegenerative Diseases Drug Revenue
3.4 Global Neurodegenerative Diseases Drug Market Concentration Ratio
3.4.1 Global Neurodegenerative Diseases Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Diseases Drug Revenue in 2021
3.5 Neurodegenerative Diseases Drug Key Players Head office and Area Served
3.6 Key Players Neurodegenerative Diseases Drug Product Solution and Service
3.7 Date of Enter into Neurodegenerative Diseases Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurodegenerative Diseases Drug Breakdown Data by Type
4.1 Global Neurodegenerative Diseases Drug Historic Market Size by Type (2017-2022)
4.2 Global Neurodegenerative Diseases Drug Forecasted Market Size by Type (2023-2028)
5 Neurodegenerative Diseases Drug Breakdown Data by Application
5.1 Global Neurodegenerative Diseases Drug Historic Market Size by Application (2017-2022)
5.2 Global Neurodegenerative Diseases Drug Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Neurodegenerative Diseases Drug Market Size (2017-2028)
6.2 North America Neurodegenerative Diseases Drug Market Size by Type
6.2.1 North America Neurodegenerative Diseases Drug Market Size by Type (2017-2022)
6.2.2 North America Neurodegenerative Diseases Drug Market Size by Type (2023-2028)
6.2.3 North America Neurodegenerative Diseases Drug Market Share by Type (2017-2028)
6.3 North America Neurodegenerative Diseases Drug Market Size by Application
6.3.1 North America Neurodegenerative Diseases Drug Market Size by Application (2017-2022)
6.3.2 North America Neurodegenerative Diseases Drug Market Size by Application (2023-2028)
6.3.3 North America Neurodegenerative Diseases Drug Market Share by Application (2017-2028)
6.4 North America Neurodegenerative Diseases Drug Market Size by Country
6.4.1 North America Neurodegenerative Diseases Drug Market Size by Country (2017-2022)
6.4.2 North America Neurodegenerative Diseases Drug Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Neurodegenerative Diseases Drug Market Size (2017-2028)
7.2 Europe Neurodegenerative Diseases Drug Market Size by Type
7.2.1 Europe Neurodegenerative Diseases Drug Market Size by Type (2017-2022)
7.2.2 Europe Neurodegenerative Diseases Drug Market Size by Type (2023-2028)
7.2.3 Europe Neurodegenerative Diseases Drug Market Share by Type (2017-2028)
7.3 Europe Neurodegenerative Diseases Drug Market Size by Application
7.3.1 Europe Neurodegenerative Diseases Drug Market Size by Application (2017-2022)
7.3.2 Europe Neurodegenerative Diseases Drug Market Size by Application (2023-2028)
7.3.3 Europe Neurodegenerative Diseases Drug Market Share by Application (2017-2028)
7.4 Europe Neurodegenerative Diseases Drug Market Size by Country
7.4.1 Europe Neurodegenerative Diseases Drug Market Size by Country (2017-2022)
7.4.2 Europe Neurodegenerative Diseases Drug Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neurodegenerative Diseases Drug Market Size (2017-2028)
8.2 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Type
8.2.1 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Neurodegenerative Diseases Drug Market Share by Type (2017-2028)
8.3 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Application
8.3.1 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Neurodegenerative Diseases Drug Market Share by Application (2017-2028)
8.4 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Region
8.4.1 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Neurodegenerative Diseases Drug Market Size (2017-2028)
9.2 Latin America Neurodegenerative Diseases Drug Market Size by Type
9.2.1 Latin America Neurodegenerative Diseases Drug Market Size by Type (2017-2022)
9.2.2 Latin America Neurodegenerative Diseases Drug Market Size by Type (2023-2028)
9.2.3 Latin America Neurodegenerative Diseases Drug Market Share by Type (2017-2028)
9.3 Latin America Neurodegenerative Diseases Drug Market Size by Application
9.3.1 Latin America Neurodegenerative Diseases Drug Market Size by Application (2017-2022)
9.3.2 Latin America Neurodegenerative Diseases Drug Market Size by Application (2023-2028)
9.3.3 Latin America Neurodegenerative Diseases Drug Market Share by Application (2017-2028)
9.4 Latin America Neurodegenerative Diseases Drug Market Size by Country
9.4.1 Latin America Neurodegenerative Diseases Drug Market Size by Country (2017-2022)
9.4.2 Latin America Neurodegenerative Diseases Drug Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neurodegenerative Diseases Drug Market Size (2017-2028)
10.2 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Type
10.2.1 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Neurodegenerative Diseases Drug Market Share by Type (2017-2028)
10.3 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Application
10.3.1 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Neurodegenerative Diseases Drug Market Share by Application (2017-2028)
10.4 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Country
10.4.1 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Details
11.1.2 Biogen Business Overview
11.1.3 Biogen Neurodegenerative Diseases Drug Introduction
11.1.4 Biogen Revenue in Neurodegenerative Diseases Drug Business (2017-2022)
11.1.5 Biogen Recent Developments
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Neurodegenerative Diseases Drug Introduction
11.2.4 Pfizer Revenue in Neurodegenerative Diseases Drug Business (2017-2022)
11.2.5 Pfizer Recent Developments
11.3 Roche
11.3.1 Roche Company Details
11.3.2 Roche Business Overview
11.3.3 Roche Neurodegenerative Diseases Drug Introduction
11.3.4 Roche Revenue in Neurodegenerative Diseases Drug Business (2017-2022)
11.3.5 Roche Recent Developments
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Neurodegenerative Diseases Drug Introduction
11.4.4 Novartis Revenue in Neurodegenerative Diseases Drug Business (2017-2022)
11.4.5 Novartis Recent Developments
11.5 Sanofi
11.5.1 Sanofi Company Details
11.5.2 Sanofi Business Overview
11.5.3 Sanofi Neurodegenerative Diseases Drug Introduction
11.5.4 Sanofi Revenue in Neurodegenerative Diseases Drug Business (2017-2022)
11.5.5 Sanofi Recent Developments
11.6 Teva Pharmaceuticals
11.6.1 Teva Pharmaceuticals Company Details
11.6.2 Teva Pharmaceuticals Business Overview
11.6.3 Teva Pharmaceuticals Neurodegenerative Diseases Drug Introduction
11.6.4 Teva Pharmaceuticals Revenue in Neurodegenerative Diseases Drug Business (2017-2022)
11.6.5 Teva Pharmaceuticals Recent Developments
11.7 Orion Pharma Ltd
11.7.1 Orion Pharma Ltd Company Details
11.7.2 Orion Pharma Ltd Business Overview
11.7.3 Orion Pharma Ltd Neurodegenerative Diseases Drug Introduction
11.7.4 Orion Pharma Ltd Revenue in Neurodegenerative Diseases Drug Business (2017-2022)
11.7.5 Orion Pharma Ltd Recent Developments
11.8 UCB S.A
11.8.1 UCB S.A Company Details
11.8.2 UCB S.A Business Overview
11.8.3 UCB S.A Neurodegenerative Diseases Drug Introduction
11.8.4 UCB S.A Revenue in Neurodegenerative Diseases Drug Business (2017-2022)
11.8.5 UCB S.A Recent Developments
11.9 ACADIA Pharmaceuticals Inc.
11.9.1 ACADIA Pharmaceuticals Inc. Company Details
11.9.2 ACADIA Pharmaceuticals Inc. Business Overview
11.9.3 ACADIA Pharmaceuticals Inc. Neurodegenerative Diseases Drug Introduction
11.9.4 ACADIA Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Drug Business (2017-2022)
11.9.5 ACADIA Pharmaceuticals Inc. Recent Developments
11.10 Lundbeck Pharmaceuticals Italy S.p.A.
11.10.1 Lundbeck Pharmaceuticals Italy S.p.A. Company Details
11.10.2 Lundbeck Pharmaceuticals Italy S.p.A. Business Overview
11.10.3 Lundbeck Pharmaceuticals Italy S.p.A. Neurodegenerative Diseases Drug Introduction
11.10.4 Lundbeck Pharmaceuticals Italy S.p.A. Revenue in Neurodegenerative Diseases Drug Business (2017-2022)
11.10.5 Lundbeck Pharmaceuticals Italy S.p.A. Recent Developments
11.11 Mitsubishi Tanabe Pharma America
11.11.1 Mitsubishi Tanabe Pharma America Company Details
11.11.2 Mitsubishi Tanabe Pharma America Business Overview
11.11.3 Mitsubishi Tanabe Pharma America Neurodegenerative Diseases Drug Introduction
11.11.4 Mitsubishi Tanabe Pharma America Revenue in Neurodegenerative Diseases Drug Business (2017-2022)
11.11.5 Mitsubishi Tanabe Pharma America Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
List of Tables
    Table 1. Global Neurodegenerative Diseases Drug Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
    Table 2. Key Players of Immunomodulator
    Table 3. Key Players of Interferons
    Table 4. Key Players of Decarboxylase Inhibitors
    Table 5. Key Players of Dopamine Agonists
    Table 6. Key Players of Others
    Table 7. Global Neurodegenerative Diseases Drug Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
    Table 8. Global Neurodegenerative Diseases Drug Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 9. Global Neurodegenerative Diseases Drug Market Size by Region (2017-2022) & (US$ Million)
    Table 10. Global Neurodegenerative Diseases Drug Market Share by Region (2017-2022)
    Table 11. Global Neurodegenerative Diseases Drug Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 12. Global Neurodegenerative Diseases Drug Market Share by Region (2023-2028)
    Table 13. Neurodegenerative Diseases Drug Market Trends
    Table 14. Neurodegenerative Diseases Drug Market Drivers
    Table 15. Neurodegenerative Diseases Drug Market Challenges
    Table 16. Neurodegenerative Diseases Drug Market Restraints
    Table 17. Global Neurodegenerative Diseases Drug Revenue by Players (2017-2022) & (US$ Million)
    Table 18. Global Neurodegenerative Diseases Drug Revenue Share by Players (2017-2022)
    Table 19. Global Top Neurodegenerative Diseases Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Diseases Drug as of 2021)
    Table 20. Ranking of Global Top Neurodegenerative Diseases Drug Companies by Revenue (US$ Million) in 2021
    Table 21. Global 5 Largest Players Market Share by Neurodegenerative Diseases Drug Revenue (CR5 and HHI) & (2017-2022)
    Table 22. Key Players Headquarters and Area Served
    Table 23. Key Players Neurodegenerative Diseases Drug Product Solution and Service
    Table 24. Date of Enter into Neurodegenerative Diseases Drug Market
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Neurodegenerative Diseases Drug Market Size by Type (2017-2022) & (US$ Million)
    Table 27. Global Neurodegenerative Diseases Drug Revenue Market Share by Type (2017-2022)
    Table 28. Global Neurodegenerative Diseases Drug Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 29. Global Neurodegenerative Diseases Drug Revenue Market Share by Type (2023-2028)
    Table 30. Global Neurodegenerative Diseases Drug Market Size by Application (2017-2022) & (US$ Million)
    Table 31. Global Neurodegenerative Diseases Drug Revenue Share by Application (2017-2022)
    Table 32. Global Neurodegenerative Diseases Drug Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 33. Global Neurodegenerative Diseases Drug Revenue Share by Application (2023-2028)
    Table 34. North America Neurodegenerative Diseases Drug Market Size by Type (2017-2022) & (US$ Million)
    Table 35. North America Neurodegenerative Diseases Drug Market Size by Type (2023-2028) & (US$ Million)
    Table 36. North America Neurodegenerative Diseases Drug Market Size by Application (2017-2022) & (US$ Million)
    Table 37. North America Neurodegenerative Diseases Drug Market Size by Application (2023-2028) & (US$ Million)
    Table 38. North America Neurodegenerative Diseases Drug Market Size by Country (2017-2022) & (US$ Million)
    Table 39. North America Neurodegenerative Diseases Drug Market Size by Country (2023-2028) & (US$ Million)
    Table 40. Europe Neurodegenerative Diseases Drug Market Size by Type (2017-2022) & (US$ Million)
    Table 41. Europe Neurodegenerative Diseases Drug Market Size by Type (2023-2028) & (US$ Million)
    Table 42. Europe Neurodegenerative Diseases Drug Market Size by Application (2017-2022) & (US$ Million)
    Table 43. Europe Neurodegenerative Diseases Drug Market Size by Application (2023-2028) & (US$ Million)
    Table 44. Europe Neurodegenerative Diseases Drug Market Size by Country (2017-2022) & (US$ Million)
    Table 45. Europe Neurodegenerative Diseases Drug Market Size by Country (2023-2028) & (US$ Million)
    Table 46. Asia Pacific Neurodegenerative Diseases Drug Market Size by Type (2017-2022) & (US$ Million)
    Table 47. Asia Pacific Neurodegenerative Diseases Drug Market Size by Type (2023-2028) & (US$ Million)
    Table 48. Asia Pacific Neurodegenerative Diseases Drug Market Size by Application (2017-2022) & (US$ Million)
    Table 49. Asia Pacific Neurodegenerative Diseases Drug Market Size by Application (2023-2028) & (US$ Million)
    Table 50. Asia Pacific Neurodegenerative Diseases Drug Market Size by Region (2017-2022) & (US$ Million)
    Table 51. Asia Pacific Neurodegenerative Diseases Drug Market Size by Region (2023-2028) & (US$ Million)
    Table 52. Latin America Neurodegenerative Diseases Drug Market Size by Type (2017-2022) & (US$ Million)
    Table 53. Latin America Neurodegenerative Diseases Drug Market Size by Type (2023-2028) & (US$ Million)
    Table 54. Latin America Neurodegenerative Diseases Drug Market Size by Application (2017-2022) & (US$ Million)
    Table 55. Latin America Neurodegenerative Diseases Drug Market Size by Application (2023-2028) & (US$ Million)
    Table 56. Latin America Neurodegenerative Diseases Drug Market Size by Country (2017-2022) & (US$ Million)
    Table 57. Latin America Neurodegenerative Diseases Drug Market Size by Country (2023-2028) & (US$ Million)
    Table 58. Middle East and Africa Neurodegenerative Diseases Drug Market Size by Type (2017-2022) & (US$ Million)
    Table 59. Middle East and Africa Neurodegenerative Diseases Drug Market Size by Type (2023-2028) & (US$ Million)
    Table 60. Middle East and Africa Neurodegenerative Diseases Drug Market Size by Application (2017-2022) & (US$ Million)
    Table 61. Middle East and Africa Neurodegenerative Diseases Drug Market Size by Application (2023-2028) & (US$ Million)
    Table 62. Middle East and Africa Neurodegenerative Diseases Drug Market Size by Country (2017-2022) & (US$ Million)
    Table 63. Middle East and Africa Neurodegenerative Diseases Drug Market Size by Country (2023-2028) & (US$ Million)
    Table 64. Biogen Company Details
    Table 65. Biogen Business Overview
    Table 66. Biogen Neurodegenerative Diseases Drug Product
    Table 67. Biogen Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
    Table 68. Biogen Recent Developments
    Table 69. Pfizer Company Details
    Table 70. Pfizer Business Overview
    Table 71. Pfizer Neurodegenerative Diseases Drug Product
    Table 72. Pfizer Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
    Table 73. Pfizer Recent Developments
    Table 74. Roche Company Details
    Table 75. Roche Business Overview
    Table 76. Roche Neurodegenerative Diseases Drug Product
    Table 77. Roche Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
    Table 78. Roche Recent Developments
    Table 79. Novartis Company Details
    Table 80. Novartis Business Overview
    Table 81. Novartis Neurodegenerative Diseases Drug Product
    Table 82. Novartis Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
    Table 83. Novartis Recent Developments
    Table 84. Sanofi Company Details
    Table 85. Sanofi Business Overview
    Table 86. Sanofi Neurodegenerative Diseases Drug Product
    Table 87. Sanofi Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
    Table 88. Sanofi Recent Developments
    Table 89. Teva Pharmaceuticals Company Details
    Table 90. Teva Pharmaceuticals Business Overview
    Table 91. Teva Pharmaceuticals Neurodegenerative Diseases Drug Product
    Table 92. Teva Pharmaceuticals Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
    Table 93. Teva Pharmaceuticals Recent Developments
    Table 94. Orion Pharma Ltd Company Details
    Table 95. Orion Pharma Ltd Business Overview
    Table 96. Orion Pharma Ltd Neurodegenerative Diseases Drug Product
    Table 97. Orion Pharma Ltd Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
    Table 98. Orion Pharma Ltd Recent Developments
    Table 99. UCB S.A Company Details
    Table 100. UCB S.A Business Overview
    Table 101. UCB S.A Neurodegenerative Diseases Drug Product
    Table 102. UCB S.A Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
    Table 103. UCB S.A Recent Developments
    Table 104. ACADIA Pharmaceuticals Inc. Company Details
    Table 105. ACADIA Pharmaceuticals Inc. Business Overview
    Table 106. ACADIA Pharmaceuticals Inc. Neurodegenerative Diseases Drug Product
    Table 107. ACADIA Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
    Table 108. ACADIA Pharmaceuticals Inc. Recent Developments
    Table 109. Lundbeck Pharmaceuticals Italy S.p.A. Company Details
    Table 110. Lundbeck Pharmaceuticals Italy S.p.A. Business Overview
    Table 111. Lundbeck Pharmaceuticals Italy S.p.A. Neurodegenerative Diseases Drug Product
    Table 112. Lundbeck Pharmaceuticals Italy S.p.A. Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
    Table 113. Lundbeck Pharmaceuticals Italy S.p.A. Recent Developments
    Table 114. Mitsubishi Tanabe Pharma America Company Details
    Table 115. Mitsubishi Tanabe Pharma America Business Overview
    Table 116. Mitsubishi Tanabe Pharma America Neurodegenerative Diseases Drug Product
    Table 117. Mitsubishi Tanabe Pharma America Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
    Table 118. Mitsubishi Tanabe Pharma America Recent Developments
    Table 119. Research Programs/Design for This Report
    Table 120. Key Data Information from Secondary Sources
    Table 121. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Neurodegenerative Diseases Drug Market Share by Type: 2021 VS 2028
    Figure 2. Immunomodulator Features
    Figure 3. Interferons Features
    Figure 4. Decarboxylase Inhibitors Features
    Figure 5. Dopamine Agonists Features
    Figure 6. Others Features
    Figure 7. Global Neurodegenerative Diseases Drug Market Share by Application: 2021 VS 2028
    Figure 8. Multiple Sclerosis Case Studies
    Figure 9. Parkinson’s Disease Case Studies
    Figure 10. Alzheimer’s Disease Case Studies
    Figure 11. Spinal Muscular Atrophy (SMA) Case Studies
    Figure 12. Others Case Studies
    Figure 13. Neurodegenerative Diseases Drug Report Years Considered
    Figure 14. Global Neurodegenerative Diseases Drug Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 15. Global Neurodegenerative Diseases Drug Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 16. Global Neurodegenerative Diseases Drug Market Share by Region: 2021 VS 2028
    Figure 17. Global Neurodegenerative Diseases Drug Market Share by Players in 2021
    Figure 18. Global Top Neurodegenerative Diseases Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Diseases Drug as of 2021)
    Figure 19. The Top 10 and 5 Players Market Share by Neurodegenerative Diseases Drug Revenue in 2021
    Figure 20. North America Neurodegenerative Diseases Drug Market Size YoY (2017-2028) & (US$ Million)
    Figure 21. North America Neurodegenerative Diseases Drug Market Size Market Share by Type (2017-2028)
    Figure 22. North America Neurodegenerative Diseases Drug Market Size Market Share by Application (2017-2028)
    Figure 23. North America Neurodegenerative Diseases Drug Market Size Share by Country (2017-2028)
    Figure 24. United States Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 25. Canada Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 26. Europe Neurodegenerative Diseases Drug Market Size YoY (2017-2028) & (US$ Million)
    Figure 27. Europe Neurodegenerative Diseases Drug Market Size Market Share by Type (2017-2028)
    Figure 28. Europe Neurodegenerative Diseases Drug Market Size Market Share by Application (2017-2028)
    Figure 29. Europe Neurodegenerative Diseases Drug Market Size Share by Country (2017-2028)
    Figure 30. Germany Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. France Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. U.K. Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. Italy Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. Russia Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 35. Nordic Countries Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 36. Asia-Pacific Neurodegenerative Diseases Drug Market Size YoY (2017-2028) & (US$ Million)
    Figure 37. Asia Pacific Neurodegenerative Diseases Drug Market Size Market Share by Type (2017-2028)
    Figure 38. Asia Pacific Neurodegenerative Diseases Drug Market Size Market Share by Application (2017-2028)
    Figure 39. Asia Pacific Neurodegenerative Diseases Drug Market Size Share by Region (2017-2028)
    Figure 40. China Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. Japan Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. South Korea Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 43. Southeast Asia Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 44. India Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 45. Australia Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
    Figure 46. Latin America Neurodegenerative Diseases Drug Market Size YoY (2017-2028) & (US$ Million)
    Figure 47. Latin America Neurodegenerative Diseases Drug Market Size Market Share by Type (2017-2028)
    Figure 48. Latin America Neurodegenerative Diseases Drug Market Size Market Share by Application (2017-2028)
    Figure 49. Latin America Neurodegenerative Diseases Drug Market Size Share by Country (2017-2028)
    Figure 50. Mexico Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 51. Brazil Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 52. Middle East & Africa Neurodegenerative Diseases Drug Market Size YoY (2017-2028) & (US$ Million)
    Figure 53. Middle East and Africa Neurodegenerative Diseases Drug Market Size Market Share by Type (2017-2028)
    Figure 54. Middle East and Africa Neurodegenerative Diseases Drug Market Size Market Share by Application (2017-2028)
    Figure 55. Middle East and Africa Neurodegenerative Diseases Drug Market Size Share by Country (2017-2028)
    Figure 56. Turkey Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 57. Saudi Arabia Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 58. UAE Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 59. Biogen Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
    Figure 60. Pfizer Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
    Figure 61. Roche Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
    Figure 62. Novartis Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
    Figure 63. Sanofi Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
    Figure 64. Teva Pharmaceuticals Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
    Figure 65. Orion Pharma Ltd Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
    Figure 66. UCB S.A Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
    Figure 67. ACADIA Pharmaceuticals Inc. Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
    Figure 68. Lundbeck Pharmaceuticals Italy S.p.A. Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
    Figure 69. Mitsubishi Tanabe Pharma America Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
    Figure 70. Bottom-up and Top-down Approaches for This Report
    Figure 71. Data Triangulation
    Figure 72. Key Executives Interviewed
SELECT A FORMAT
Added to Cart

Electronic (PDF)
$4900
This license allows only one user(purchaser of the report) to access the PDF.

Electronic (PDF)
$7350
This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Electronic (PDF)
$9800
This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Accenture

RELATED REPORTS

Global and United States Biologics Drug Development Market Report Forecast 2022 2028
Global and United States Biologics Drug Development Market Report & Forecast 2022-2028

120 Pages
Type: Report
Code: QYRE-Auto-5X6010
Tue Jun 07 00:00:00 UTC 2022

Add to Cart

Global and United States Biologics Drug Discovery Market Report Forecast 2022 2028
Global and United States Biologics Drug Discovery Market Report & Forecast 2022-2028

120 Pages
Type: Report
Code: QYRE-Auto-0D6239
Tue Jun 07 00:00:00 UTC 2022

Add to Cart

Global and United States Nanopharmaceutical Drugs Market Report Forecast 2022 2028
Global and United States Nanopharmaceutical Drugs Market Report & Forecast 2022-2028

The increasing prevalence of chronic diseases and development of the healthcare infrastructure are promoting the adoption of the novel medicine known as nanomedicine for better efficacy and improved patient outcome.Market Analysis and Insights Global and United States Nanopharmaceutical Drugs MarketThis report focuses on global and United States Nanopharmaceutical Drugs market also covers the segmentation data of other regions in regional level and county level.Due to the COVID19 pandemic the global Nanopharmaceutical Drugs market size is estimated to be worth US 35330 million in 2022 and is forecast to a readjusted size of US 72540 million by 2028 with a CAGR of 12.7 during the review period.

120 Pages
Type: Report
Code: QYRE-Auto-24J10248
Tue Jun 07 00:00:00 UTC 2022

Add to Cart

Global and United States Polymerase Chain Reaction Technology Market Report Forecast 2022 2028
Global and United States Polymerase Chain Reaction Technology Market Report & Forecast 2022-2028

120 Pages
Type: Report
Code: QYRE-Auto-7I6111
Tue Jun 07 00:00:00 UTC 2022

Add to Cart